Company profile for Eris Lifesciences

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Eris Lifesciences Ltd is a leading Indian pharmaceutical company, ranked #21 in the IPM, specializing in chronic and sub-chronic therapies (~87% of revenue). Established in 2007, it dominates the cardio-metabolic segment while expanding into dermatology, neuropsychiatry, and gynecology (26% of revenue). With a strong presence in India’s ₹55,000+ crore chronic care market, Eris focuses on specialist-driven, innovative treat...
Eris Lifesciences Ltd is a leading Indian pharmaceutical company, ranked #21 in the IPM, specializing in chronic and sub-chronic therapies (~87% of revenue). Established in 2007, it dominates the cardio-metabolic segment while expanding into dermatology, neuropsychiatry, and gynecology (26% of revenue). With a strong presence in India’s ₹55,000+ crore chronic care market, Eris focuses on specialist-driven, innovative treatments to improve patient outcomes. The company combines cutting-edge medical knowledge with a robust branded formulations portfolio, serving high-end physicians and delivering consistent growth.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
India
Address
Address
Shivarth Ambit, Plot No 142/2, Ramdas Road Off SBR, Near Swati Bungalows, Boda...
Telephone
Telephone
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Default Event

BioProcess International US West

Not Confirmed

envelop Contact Supplier

BioProcess International US West

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.indianpharmapost.com/news/eris-lifesciences-partnership-with-natco-pharma-for-semaglutide-launch-in-india-19198

INDPHARMAPOST
25 Feb 2026

https://www.pharmabiz.com/NewsDetails.aspx?aid=183674&sid=1

PHARMABIZ
21 Jan 2026
Delhi HC Restores Ban On 2 Diabetes FDCs
Delhi HC Restores Ban On 2 Diabetes FDCs

14 Jan 2026

// ECONOMICTIMES

https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/delhi-hc-restores-ban-on-2-diabetes-fdcs/articleshow/126532810.cms

ECONOMICTIMES
14 Jan 2026

https://www.indianpharmapost.com/news/eris-lifesciences-consolidates-its-stake-in-swiss-parenterals-18354

INDPHARMAPOST
25 Nov 2025

https://www.business-standard.com/industry/news/indian-drugmakers-eye-rs800cr-opportunity-as-novo-exits-insulin-pens-125092200599_1.html

BUSINESS STD
22 Sep 2025

https://www.indianpharmapost.com/drug-approval/eris-lifesciences-receives-anvisa-approval-at-its-ahmedabad-campus-17654

INDPHARMAPOST
25 Aug 2025

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty